MedTrace Logo

Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis

NCT06009094 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-12-10

No results posted yet for this study

Summary

This study is a single center, randomized, double-blind, Vehicle controlled,, single and multiple dose clinical study.

Conditions

Interventions

DRUG

VC005

VC005 group with Local topical application

DRUG

VC005 Placebo

VC005 Placebo group with Local topical application

Sponsors & Collaborators

  • Jiangsu vcare pharmaceutical technology co., LTD

    lead INDUSTRY

Principal Investigators

  • Qianjin Lu · Chinese Academy of Medical Sciences Hospital of Skin Disease

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-27
Primary Completion
2024-05-23
Completion
2024-05-23

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06009094 on ClinicalTrials.gov